KRAS mutations are associated with inferior clinical outcome in patients with metastatic colorectal cancer, but are not predictive for benefit with cediranibJohn Smith, Juliane M. Jürgensmeier, Paulo M. Hoff et al.|European Journal of Cancer|2013Cited by 16